By VETTAPHARMA reporter: New long-term data from Eli Lilly and Company reveal that Omvoh (mirikizumab-mrkz) helped patients with moderately to severely active Crohn’s disease maintain steroid-free remission for three years, underscoring sustained efficacy and potential to significantly alter disease outcomes.
Data presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) in Stockholm showed that among patients who achieved steroid-free remission at one year, more than 90% sustained that remission through three years of continuous Omvoh treatment.
In the Phase 3 VIVID-2 open-label extension study, patients with an endoscopic response at one year in the core VIVID-1 trial sustained clinical benefits through week 152 (three years). Clinical remission rates at 152 weeks were 92.4%, and corticosteroid-free clinical remission was 91.2%.
Additional patient-reported outcomes showed that 82.1% achieved a ≥3-point reduction on the Urgency Numeric Rating Scale (UNRS) and 71.7% achieved UNRS scores of ≤2, indicating meaningful improvement in bowel urgency symptoms — a key quality-of-life measure.
Experts say such durable control without corticosteroids is crucial given the chronic and unpredictable nature of Crohn’s disease, where recurrent inflammation often leads to hospitalizations or surgery if remission isn’t maintained.
The data also complement findings from additional Lilly trials showing very low rates of Crohn’s-related hospitalizations and surgeries in patients treated with Omvoh and consistent long-term safety.
Omvoh works as a selective IL-23p19 antagonist, targeting a pathway involved in inflammatory bowel disease. It is already approved in multiple countries for both Crohn’s disease and ulcerative colitis, marking it as a key long-term treatment option for adults with moderately to severely active disease.
Source credit:
- Eli Lilly and Company. (2026, February 19). Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz). Click here
